Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study Meeting Abstract
| Authors: | Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L. J.; Wei, M. C.; Yin, S.; To, I.; Huang, H.; Min, J.; Penuel, E.; Budde, L. E. |
| Abstract Title: | Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 1467 |
| End Page: | 1470 |
| Language: | English |
| ACCESSION: | WOS:000893223201196 |
| DOI: | 10.1182/blood-2022-157691 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
